Adalimumab is a type of drug that is called a biologic. It is an effective treatment for JIA-associated uveitis and is taken in the form of a subcutaneous injection.
Many people with JIA take adalimumab to control their joint and eye inflammation. While adalimumab is effective in controlling eye and joint inflammation, there are some risks such as infection associated with the medication. Adalimumab can also be very expensive.
A clinical trial will be conducted to compare control of eye inflammation (uveitis) and arthritis in patients with JIA who stop adalimumab vs. continue adalimumab. Recruitment for the trial will begin in early 2020.
